Analyst Ratings February 19, 2026

UBS Moves XL Axiata to Neutral, Lowers Price Target Citing Valuation

Broker sees balanced risk-reward as trading multiples and merger clarity dictate near-term performance

By Hana Yamamoto EXCL PTXKY
UBS Moves XL Axiata to Neutral, Lowers Price Target Citing Valuation
EXCL PTXKY

UBS raised its recommendation on XL Axiata to Neutral from Sell while trimming its price target to IDR3,300 from IDR3,600. The bank cites stretched valuation metrics and the need for clearer merger synergy evidence before earnings momentum emerges, even as pricing trends and ARPU gains show improvement.

Key Points

  • UBS upgraded XL Axiata to Neutral from Sell and cut its price target to IDR3,300 from IDR3,600.
  • The stock yields 3.4% and has paid dividends for six consecutive years; it fell 36% after MSCIs review of Indonesian equities.
  • Valuation metrics are mixed - UBS cites 5x 2027E EV/EBITDA (1 standard deviation above the five-year mean) while current EV/EBITDA is 9.96x; ARPU growth exceeded 10% q/q in Q4 for both Indosat and XL.

UBS revised its view on XL Axiata Tbk, upgrading the Indonesian telecommunications operator from Sell to Neutral and reducing its price target to IDR3,300 from IDR3,600. The brokernoted valuation dynamics and the companys profit trajectory as central to its reassessment.

XL Axiata currently yields 3.4% in dividends and has maintained distributions for six consecutive years, providing income continuity for shareholders. The stock experienced a 36% drop following MSCI's review of Indonesian equities and, according to UBS, now trades at 5x 2027E EV/EBITDA - a level described as one standard deviation above its five-year mean. UBS also reports a current EV/EBITDA of 9.96x and a beta of -0.19, indicating the stock has tended to move inversely to broader market swings.

On the operational front, UBS highlighted favorable pricing dynamics in the market. It pointed to better-than-expected ARPU performance in the fourth quarter, with both Indosat and XL delivering more than 10% quarter-over-quarter growth in ARPU. These pricing trends contrast with some investor concerns about profitability.

Revenue growth was noted at 23.42%, yet consensus forecasts have been revised downwards and now imply that losses could persist into 2026. This view aligns with data showing XL Axiata was not profitable over the most recent twelve-month period, as reported through market data services referenced by UBS.

Given the current picture, UBS expects the shares to trade in a sideways pattern - a dynamic the bank compares to Indosat's behaviour in 2022 - unless there is clearer evidence that merger-related synergies will produce an inflection in earnings growth. On balance, the firm judges the stock's risk-reward profile to be balanced at present.


Context and implications

The upgrade to Neutral reflects UBSs view that valuation and operational signals are offsetting: stronger ARPU progression and steady dividend policy versus stretched EV/EBITDA and ongoing consensus expectations of losses. For investors, the broker's guidance implies limited near-term upside without demonstrable merger benefits or improved profitability metrics.

Risks

  • Uncertainty over merger synergies - UBS expects sideways trading until clearer proof of earnings inflection from any merger-related benefits emerges. This affects telecom sector valuations and potential consolidation outcomes.
  • Consensus downward revisions and projected losses into 2026 - market earnings expectations have weakened, reflecting profitability risk for equity investors in the telecommunications sector.
  • Index adjustments - the stocks 36% decline following MSCIs review illustrates the vulnerability of Indonesian equities to index rebalancing and related passive flows.

More from Analyst Ratings

DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026